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Abstract
Aim Acetaminophen is a commonly used medicine for pain relief and emerging evidence suggests that it may improve endur-
ance exercise performance. This study investigated some of the physiological mechanisms by which acute acetaminophen 
ingestion might blunt muscle fatigue development.
Methods Thirteen active males completed 60 × 3 s maximum voluntary contractions (MVC) of the knee extensors with each 
contraction separated by a 2 s passive recovery period. This protocol was completed 60 min after ingesting 1 g of malto-
dextrin (placebo) or 1 g of acetaminophen on two separate visits. Peripheral nerve stimulation was administered every 6th 
contraction for assessment of neuromuscular fatigue development, with the critical torque (CT), which reflects the maximal 
sustainable rate of oxidative metabolism, taken as the mean torque over the last 12 contractions. Surface electromyography 
was recorded continuously as a measure of muscle activation.
Results Mean torque (61 ± 11 vs. 58 ± 14% pre-exercise MVC) and CT (44 ± 13 vs. 40 ± 15% pre-exercise MVC) were 
greater in the acetaminophen trial compared to placebo (both P < 0.05). Voluntary activation and potentiated twitch declined 
at a similar rate in both conditions (P > 0.05). However, the decline in electromyography amplitude was attenuated in the 
acetaminophen trial, with electromyography amplitude being greater compared to placebo from 210 s onwards (P < 0.05).
Conclusion These findings indicate that acute acetaminophen ingestion might be ergogenic by increasing CT and preserving 
muscle activation during high-intensity exercise.
Keywords Analgesic · Critical torque · Electromyography · Neuromuscular fatigue · Single-leg exercise
Abbreviations
ACT  Acetaminophen (paracetamol)
CT  Critical torque (i.e., asymptote of the torque-
time to exhaustion relationship)
EMG  Electromyography
EMGRMS  EMG amplitude using root mean square 
method
M-wave  M-wave amplitude
Mmax  Maximal m-wave amplitude
MVC  Maximal voluntary contraction
PL  Placebo
pTw  Potentiated twitch
RMS  Root mean square
rTw  Resting twitch
sTw  Superimposed twitch (onto an MVC)
VA  Voluntary activation (%)
W′  Curvature constant of the hyperbolic Torque-
time to exhaustion relationship
Introduction
Neuromuscular fatigue is defined as a decrease in skel-
etal muscle force production capacity (Gandevia 2001). 
This neuromuscular fatigue development can arise from 
physiological perturbations within the central nervous 
system, termed central fatigue, or within, or distal to, the 
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neuromuscular junction, termed peripheral fatigue (Gan-
devia 2001). Exercise-induced fatigue is a complex, multi-
factorial process, the physiological bases of which are still 
widely debated (Enoka and Duchateau 2008; Gandevia 
2001; Hureau et al. 2016; Place et al. 2010; Taylor et al. 
2016). Indeed, recent research suggests that peripheral 
fatigue and central fatigue develop inter-dependently and 
are likely to interact in a coordinated manner to determine 
neuromuscular fatigue development (Hureau et al. 2016).
Following the onset of muscle contractions, group III 
and IV afferents discharge in response to mechanical and 
metabolic stimuli, contributing to the sensation of muscle 
pain during exercise (O’Connor and Cook 1999; McCord 
and Kaufmann 2010; Pollak et al. 2014). Group III/IV mus-
cle afferent feedback, and the associated sensation of pain, 
appears to play a role in neuromuscular fatigue development 
through modulating both central and peripheral fatigue. 
Indeed, when the ascending projection of group III and IV 
muscle afferents is attenuated via intrathecal fentanyl admin-
istration, central motor drive is increased (as inferred via 
electromyography, EMG) and peripheral fatigue develop-
ment is expedited (Amann et al. 2009, 2011; Blain et al. 
2016). Therefore, interventions that can modulate skeletal 
muscle pain sensation have the potential to impact muscle 
activation and exercise-induced fatigue development.
Acetaminophen (ACT; or paracetamol) is a commonly 
used non-prescription pain reliever which is considered 
one of the safest non-opioid analgesics at therapeutic doses 
(Toussaint et al. 2010). Acute ACT consumption has been 
shown to improve exercise performance concomitant with 
a lower pain sensation (Foster et al. 2014; Mauger et al. 
2010). The mechanisms that underlie the analgesic effect 
of ACT are not completely understood, but are considered 
to be predominantly mediated by central factors (Ander-
son 2008; Graham et al. 2013; Smith 2009; Toussaint et al. 
2010). Conventionally, the analgesic effect of ACT has been 
attributed to the inhibition of cyclooxygenase enzymes, 
which stimulate nociceptor discharge through the synthesis 
of prostaglandins (Graham et al. 2013; Jóźwiak-Bębenista 
and; Nowak 2014). There is also evidence that the analgesic 
effect of ACT is linked to potentiation of descending sero-
toninergic pathways (Pickering et al. 2006, 2008), and to 
modulation of opioid and cannabinoid receptors (Graham 
et al. 2013). These mechanisms likely interact to lower pain 
sensation after acute ACT ingestion by increasing the noci-
oceptive stimuli required to evoke a given pain sensation. 
Although ACT ingestion has been reported to increase rest-
ing cortico-spinal excitability, as inferred from an increased 
motor evoked potential amplitude (Mauger and Hopker 
2013), the neuromuscular bases for blunted exercise-induced 
fatigue development following ACT ingestion have yet to be 
investigated.
In addition to altering pain sensation and neuromuscular 
function, ACT ingestion might attenuate fatigue develop-
ment and enhance performance by modulating aspects of 
the power or torque-duration relationship. The asymptote 
of the hyperbolic torque-duration relationship is termed the 
critical torque (CT) and can be estimated from the mean 
torque produced over the last 12 maximum voluntary con-
tractions (MVCs) of a 60 MVC knee extension protocol 
(Burnley 2009). The CT reflects the maximal sustainable 
rate of oxidative metabolism (Jones et al. 2008, 2011 for 
review) and represents a critical threshold for neuromuscular 
fatigue development (Burnley et al. 2012). The curvature 
constant of the torque-duration hyperbola is termed the W′ 
and represents a fixed amount of torque-impulse (surrogate 
measure of ‘total work’) that can be completed above CT 
(Burnley and Jones 2016; Jones et al. 2008; Poole et al. 
1988). Together, CT (critical power or critical speed for 
other forms of exercise) and W′ (or its equivalent) can be 
used to accurately predict exercise performance (Black et al. 
2014; Burnley et al. 2012). An intervention that enhances 
high-intensity exercise tolerance or performance, or attenu-
ates fatigue development, would be expected to enhance CT 
or W′ (or their exercise modality-specific equivalents). For 
example, critical power, but not W′, is increased following 
endurance training concomitant with improved endurance 
exercise performance (Vanhatalo et al. 2008). Therefore, the 
reported improvement in exercise performance with acute 
ACT ingestion (Foster et al. 2014; Mauger et al. 2010, 2014) 
would be expected to be linked to improvements in CT and/
or W′, but this has yet to be investigated.
The purpose of this study was to test the hypotheses that, 
compared to placebo, acute consumption of 1 g ACT would 
reduce the rate of neuromuscular fatigue development, and 
increase total impulse (torque-time integral), CT and muscle 
activation during a 5 min single-leg intermittent MVC test.
Materials and methods
Participants
Thirteen healthy male volunteers (mean ± SD: age 31 ± 7 
years, height 1.76 ± 0.08 m, body mass 75 ± 11 kg) provided 
written, informed consent to participate in the present study, 
which was approved by the Ethics Committee of Sport and 
Health Sciences (University of Exeter). After being informed 
of the experimental procedures and associated risks, all 
participants completed a medical health questionnaire to 
ensure they could safely consume ACT prior to performing 
exhaustive exercise. Subjects were not consumers of any 
‘pain relief’ medication (prescription or non-prescription) 
over the course of the study. None of the subjects had a his-
tory of motor or neurological disorders.
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Experimental design
Subjects visited the laboratory on three occasions over a 3- 
to 4-week period with all tests separated by at least 1 week 
and conducted at a similar time of day (± 90 min) to limit 
changes in quadriceps strength and to account for diurnal 
variations in neuromuscular excitability. The first laboratory 
visit was used to familiarise subjects to the measurements 
and experimental protocol described below. During these 
sessions, the settings and placement of the dynamometer 
and EMG and peripheral nerve stimulation electrodes were 
recorded for each subject. Subsequently, subjects performed 
the fatiguing protocol under two conditions (see ‘Experi-
mental protocol’): placebo (PL) and ACT.
Experimental protocol
Subjects completed a preliminary trial for familiarisation 
to the measurement techniques and experimental protocol. 
An isokinetic dynamometer (Biodex System 3, Shirley, NY, 
USA) was used in all tests and adjusted so that the axis of 
rotation of the lever arm was in line with the lateral epicon-
dyle of the right femur. Subjects were seated with the hip 
and knee joints at relative angles of 155° and 90°, respec-
tively. The remainder of the chair settings were recorded 
and replicated in all subsequent trials to ensure an identical 
body position was assumed throughout the experimental tri-
als. The semi-supine position was employed as it permitted 
better access to the superficial femoral nerve for peripheral 
nerve stimulation as verified during pilot testing. Inelastic 
padded Velcro straps were fastened at the ankle, quadriceps, 
hip and shoulders to maintain a stable body position. The 
procedures adopted during the familiarisation trial were rep-
licated in all experimental trials.
The trials on visits 2 and 3 were completed in a double-
blind, randomised fashion using a cross-over experimen-
tal design. Prior to each visit, subjects were required to 
refrain from caffeine (for at least 12 h), strenuous exercise 
and alcohol (for at least 24 h), analgesics and any form of 
anti-inflammatory drug (for the duration of the experimen-
tal trial) and to arrive in a fully rested and hydrated state. 
Subjects were instructed to maintain their usual diet and 
exercise regime during the study. 1 g of maltodextrin (pla-
cebo) or 1 g of acetaminophen was ingested orally, 60 min 
prior to the exercise bout such that the start of the exercise 
trial was expected to coincide with attainment of the peak 
plasma [acetaminophen] (Anderson et al. 2008; Forrest et al. 
1982). Following oral ingestion, ACT is rapidly absorbed 
from the gastrointestinal tract and its bioavailability ranges 
from 70 to 90% (Forrest et al. 1982). The trials started with 
a standardised isometric warm-up routine (10 isometric con-
tractions for 3 s at 50% of pre-exercise MVC as determined 
during familiarisation testing) and testing of the optimal 
EMG electrode, anode and cathode placement and stimula-
tion intensity for peripheral nerve stimulation. Neuromus-
cular function was assessed pre-trial, during and (< 10 s) 
post-trial. Single peripheral nerve stimulation pulses were 
manually triggered at rest to determine pre-exercise neuro-
muscular function, namely the characteristics of the M-wave 
response (M-wave amplitude; Mmax) to supramaximal nerve 
stimulation, contractility of the muscle (i.e., maximal rate 
of force development, half-relaxation time and contraction 
time), voluntary activation (VA) and potentiated twitch 
force (pTw). During MVCs, peripheral nerve stimulation 
pulses were triggered to occur as soon as a peak torque was 
achieved (typically 1.5 s into a 3 s contraction), each sepa-
rated by a 40 s rest. The stimuli were also delivered 1–2 s 
after the cessation of the contraction to provide a resting 
twitch (rTw). Identical measurements were repeated as soon 
as possible (< 10 s) after the fatiguing exercise to determine 
post-exercise neuromuscular function (see Fig. 1).
The intermittent isometric contraction protocol used in 
this study had a similar design to that presented by Burn-
ley (2009). The protocol consisted of repeated brief MVCs 
(3 s contraction, 2 s rest), timed via a visual prompt to ‘go’ 
and ‘relax’ (separate to the torque output screen), accompa-
nied by the same verbal instructions from the experimenter. 
The protocol was terminated when the subjects completed 
the 60th MVC. Every 6th contraction was accompanied 
by peripheral nerve stimulation during and post-MVC (as 
described for pre- and post-trial measurements). Subjects 
were not given a visual representation of the torque pro-
duced during each MVC or made aware of the number of 
MVCs elapsed during the protocol. Subjects were instructed 
to continue to perform maximal contractions throughout. 
The coefficient of variation for MVC performance (mean 
torque through 60 MVCs) and electromyography root mean 
square  (EMGRMS) amplitude using this experimental set up 
was 2.9% and 4.8%, respectively as calculated during pilot 
testing.
Measurements
Torque
Knee extensor torque from the Biodex isokinetic dynamom-
eter was sampled at 1000 Hz and low-pass filtered at 40 Hz, 
before being displayed on a wide screen monitor using 
Spike2 (CED, Cambridge, UK). Torque was expressed 
throughout as a percentage (%) of pre-exercise MVC.
Electromyography
Surface EMG activity was recorded from vastus lateralis, 
vastus medialis and rectus femoris of the quadriceps and 
biceps femoris of the hamstring of the right leg using active 
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bipolar bar electrodes in a single differential configuration 
(DE2.1, DelSys Inc, Boston, MA, USA). The electrodes 
were placed over the respective muscle bellies (SENIAM 
guidelines). Double-sided adhesive tape and a hypoaller-
genic medical tape were used to ensure the EMG sensor 
stability for recording electrodes. The skin area underneath 
each EMG electrode was shaved, then exfoliated and cleaned 
with alcohol to minimise the skin impedance. The EMG 
and torque signals were pre-amplified (1000×), band-pass 
filtered (20–450 Hz, Bagnoli-8, DelSys Inc, Boston, MA, 
USA), and then transferred to a computer with a sampling 
frequency of 2 kHz and high-pass filtered at 10 Hz. EMG 
and torque data were recorded continuously and digitised 
synchronously with 16 bit resolution via an A/D converter 
(± 5 V range, CED 1401 power, Cambridge, UK). The elec-
trodes were used to record: (1) evoked muscle action poten-
tial (peak-to-peak amplitude of the M-wave); and (2) EMG 
to estimate muscle activity and the output of spinal moto-
neurons (motor unit recruitment and firing frequency). EMG 
was average rectified using the root mean square method 
 (EMGRMS).  EMGRMS was then normalised to the pre-
exercise maximum (or maximal EMG signal) and the local 
M-wave amplitude (closest measure of the M-wave to the 
MVC) to exclude any changes to the EMG trace to changes 
in local excitability. The ground electrode was placed over 
the patella of the right leg.
Peripheral nerve stimulation
Electrical stimulation was applied by a constant current 
stimulator (Digitimer Stimulator DS7, Digitimer, UK). 
M-waves were elicited by supramaximal percutaneous 
electrical stimulation of the femoral nerve (200 µs dura-
tion). The cathode was placed over the femoral nerve in the 
inguinal fossa, approximately 3–5 cm below the inguinal 
ligament in the femoral triangle. Once the M-wave was elic-
ited, the maximum amplitude (peak-to-peak) of the M-wave 
was determined (Mmax) for the vastus lateralis and vastus 
medialis. To determine the stimulation intensity (current), 
single stimuli were delivered in 20 mA step-wise increments 
from 100 mA until a plateau in quadriceps rTw and M-wave 
were observed. To ensure a supramaximal response, the cur-
rent was increased by an additional 30% (mean ± SD cur-
rent = 194 ± 81 mA; Burke 2002; Goodall et al. 2010; Ney-
roud et al. 2014). The average Mmax was obtained from three 
stimuli, with ~ 8–10 s separating each pulse at rest. Peak 
torque, maximal rate of force development, half-relaxation 
time and contraction time were analysed for all rTw and 
pTw.
Data analyses
Data were analysed using a custom written script developed 
in Spike2 software (CED, Cambridge, UK). Mean torque 
MVC
A
MVC MVC MVC MVC MVC
MVC
B
MVC MVC MVC MVC
MVC
C
MVC
MVC
Fig. 1  Schematic of the procedures used prior to (panel a), during 
(panel b) and within 10 s following (panel c) the 60 maximal iso-
metric voluntary contraction (MVC) protocol. 10  s separated each 
single pulse stimulation administered at rest (small dashed arrows). 
a (pre) c (post) 45  s rest period separated maximal efforts (MVCs). 
Single pulse stimuli were administered during peak force produc-
tion of MVCs (large solid arrow) and immediately (1–2 s post; small 
grey arrows). b 60 MVC protocol of the knee extensors. The figure 
presents a period of 30  s which is repeated sequentially for 5  min. 
Each MVC was held for 3 s and interspersed by a 2 s passive recov-
ery period. Every 6th MVC was accompanied by single pulse stimuli 
administered during peak force production (large solid arrow) and 
immediately following (< 2 s post; small grey arrows). This cycle was 
repeated 10 times such that the protocol spanned 5 min requiring the 
completion of 60 MVCs. MVC, maximal voluntary isometric con-
traction. Surface electromyography (EMG) was measured throughout
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for each 3 s contraction was determined for all tests as the 
mean value over a 1 s period which approximated the plateau 
level of the highest torque (i.e., 500 ms before and after the 
peak torque). The pTw was calculated as the peak torque 
achieved following the single pulse delivered 1 s post-MVC. 
The twitch torque superimposed onto the peak force produc-
tion of the MVC (sTw) was calculated as the increment in 
torque immediately following the pulse during MVCs. The 
torque-impulse was calculated as the area under the torque-
time curve by accumulating the time integral of each MVC 
(3 s) by the difference in torque between MVCs. The end-
test torque (i.e., CT) during the 60 MVC test was defined 
as the mean of the last 12 contractions (i.e., the last 60 s; 
Burnley 2009). The W′ was calculated as the area above the 
CT from the torque-time curve (i.e., impulse above CT). 
Central fatigue was assessed as the maximal voluntary acti-
vation of the motoneuron pool (VA, %), calculated using the 
interpolated twitch method from peripheral nerve stimula-
tion (Merton 1954). Specifically, the increment in torque 
evoked during the MVCs was expressed as a fraction of the 
amplitude of the potentiated twitch produced with the same 
stimulus in the relaxed muscle post-MVC. The level of vol-
untary drive was then quantified as a percentage: [1 − evoked 
torque (superimposed on voluntary torque, sTw)/ (potenti-
ated twitch torque, pTw) × 100] (i.e., Allen at al. 1998).
The changes in maximal voluntary torque, rTw, pTw, VA 
and  EMGRMS, were used to quantify peripheral fatigue and 
central fatigue. The maximal EMG was taken from the first 
MVC during the 60 MVC task and compared to the last 
MVC at task end. The neuromuscular parameters extracted 
from the three sets of maximal contractions completed post-
exercise were tested for statistical differences between sets 
of contractions and then compared to the first set of MVCs 
completed pre-exercise (Froyd et al. 2013; Pageaux et al. 
2015; Doyle-Baker et al. 2017). Neuromuscular function was 
also measured for each of the stimulated contractions during 
the exercise and normalised to the corresponding pre-exer-
cise values at 100% MVC. All neuromuscular parameters 
and torque were averaged across the protocol using 6 (30 s) 
bin averages.
Statistics
Paired-samples t-tests were used to compare the mean 
torque, total impulse, CT and Wʹ (i.e., impulse above CT) 
between ACT and PL conditions. In addition, paired-sam-
ples t-tests were used to assess parameters of neuromuscu-
lar function at task end between trials including rTw, pTw, 
maximal rate of force development, half-relaxation time 
and contraction time. The profiles of torque, VA, pTw and 
M-wave amplitude were analysed using two-way ANOVAs 
with repeated measures (using 12 contraction averages; i.e., 
6 time points). Normalised  EMGRMS were analysed using 
two-way ANOVAs with repeated measures using 30 s mean 
values (i.e., 10 time points). Where the ANOVA revealed a 
significant interaction effect, post hoc tests were completed 
using a Bonferroni correction. For calculation of effect size, 
partial eta squared (η2) was used for omnibus tests. Cohen’s 
d was used to calculate the effect size for paired t-tests and 
post hoc comparisons. A t-test was also conducted on the 
differences in EMG and force production (torque) from task 
end (i.e., 300 s) to 150 s (mid-point) to assess the rate of 
change as the protocol progressed. All statistical tests were 
performed both on % change and raw data. Where spheric-
ity was violated, a greenhouse-geisser correction factor was 
used. For all the tests, results were considered statistically 
significant when P < 0.05. Data are presented as mean ± SD 
unless otherwise indicated. All statistical analyses were con-
ducted using IBM SPSS Statistics version 23.
Results
The mean MVC torque achieved prior to the 60 MVC pro-
tocol was 232 ± 47 and 228 ± 48 N m for PL and ACT, 
respectively. VA of the knee extensors achieved during 
the preliminary MVCs was 88 ± 7% and 87 ± 5 for PL and 
ACT, respectively. Baseline MVC and VA were not different 
between conditions (P > 0.05).
60 MVC performance
The profile for mean torque across all subjects during each 
contraction for the 60 MVC protocol and a representa-
tive individual response is shown in Fig. 2. During the PL 
trial, torque declined from a peak of 99 ± 3% MVC (rela-
tive to pre-exercise MVC) during the first contraction to 
40 ± 15% MVC during the last 12 contractions (P < 0.0001, 
η2 = 0.908; Table 1; Fig. 2). The mean torque (relative to 
pre-exercise MVC) achieved across the 60 MVCs was 
greater with ACT (61 ± 11%, 97.1 ± 23.2 N m) compared 
to PL (58 ± 14%, 83.8 ± 22.7 N m; P = 0.030, d = 0.656) 
and there was a significant interaction effect (time × con-
dition; P = 0.036, η2 = 0.260). Post hoc tests revealed sig-
nificant differences in torque between conditions at task 
end (P = 0.044, d = 0.656) but at no other time points 
(all P > 0.084 and d < 0.548). CT was higher with ACT 
compared to placebo (ACT: 44 ± 13% vs. PL: 40 ± 15%, 
P = 0.011, d = 0.691), with no between-condition differences 
in Wʹ (PL: 6.97 ± 2.43, ACT: 6.91 ± 2.54 N m s; P = 0.879, 
d = 0.026). Total impulse in the 60 MVC protocol was 
higher with ACT (24,386 ± 3793 N m s) compared to PL 
(22,055 ± 3885 N m s; P = 0.006, d = 0.973). As time pro-
gressed, the difference in force production between condi-
tions increased as evidenced by a significant difference in 
rates of change between conditions (i.e., difference between 
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300 and 150 s time points; P = 0.035, d = 0.696). The indi-
vidual responses following ACT supplementation to the 
torque-impulse can be seen in Fig. 3. Table 2 illustrates the 
parameters of the 60 MVC test for PL and ACT for indi-
vidual subjects and is available as an online supplement.
Neuromuscular function
There was a main effect for time on pTw (Fig. 4a, P < 0.001, 
η2 = 0.754), voluntary activation (Fig.  4b, P < 0.001, 
η2 = 0.647) and M-wave amplitude (Fig.  4c, P = 0.005, 
η2 = 0.281), which all declined as the protocol progressed. 
VA declined from 89 ± 8% to 59 ± 19% and from 88 ± 5% to 
62 ± 16% in the PL and ACT conditions (P < 0.0001, Fig. 3), 
respectively. However, there was no main condition effect on 
M-wave amplitude (P = 0.733, η2 = 0.012), pTw (P = 0.783, 
η2 = 0.032) or VA (P = 0.841, η2 = 0.004). Likewise, there 
was no significant interaction effect (i.e., time × condi-
tion) on M-wave amplitude (P = 0.993, η2 = 0.009) or VA 
(P = 0.387, η2 = 0.097). In addition, pTw declined from 
68 ± 8 to 30 ± 20 N m and from 71 ± 12 to 31 ± 23 N m (both 
P < 0.0001) for PL and ACT, respectively, but there was no 
significant difference in end-exercise pTw between condi-
tions (P = 0.763, d = 0.047). There was also no significant 
difference in end-exercise maximal rate of force develop-
ment (P = 0.181, d = 0.383), half-relaxation time (P = 0.234, 
d = 0.341) or contraction time (P = 0.595, d = 0.232) between 
conditions.
Fig. 2  Torque profile during the 60 maximal contractions in the pla-
cebo (clear circles) and acetaminophen (filled circles) trials. All con-
tractions were normalised to a control maximal voluntary contraction 
(MVC) performed before the test commenced. Mean ± SE torque 
responses are presented in a with the torque response from a repre-
sentative individual presented in b for the 6th and 54th contractions, 
respectively, for PL (grey line) and ACT (black line). Note that torque 
falls over the first ~ 150 s before reaching stable values between 240 
and 300  s (the end-test torque; last 12 MVCs). For b, black arrows 
indicate point of peripheral nerve stimulation
Table 1  Performance and 
neuromuscular function 
parameters of the 60 MVC 
test following placebo and 
acetaminophen ingestion
MVC maximal voluntary contraction, CT critical torque measured in the last six contractions; mean torque 
measured as average torque across the 60 MVC test, pTw potentiated twitch force, MRFD maximal rate 
of force development, VA voluntary activation measured using the interpolated twitch method technique, 
EMG electromyography, N m newton metres, N m s newton metres per second, ms milliseconds
*Significantly different from placebo (P < 0.05)
Placebo Acetaminophen
Performance
 Peak MVC (N m) 221 ± 49 230 ± 38
 Mean torque (% MVC) 58 ± 14 61 ± 11*
 Total torque-impulse (N m s) 22,055 ± 3885 24,386 ± 3792*
 CT (% MVC) 40 ± 15 44 ± 12*
 Wʹ (N m s) 6971 ± 2432 6906 ± 2537
Neuromuscular function
 End-exercise pTw (N m) 30 ± 20 31 ± 23
 End-exercise contraction time (ms) 83.2 ± 10.9 81.3 ± 14.0
 End-exercise half-relaxation time (ms) 72.5 ± 17.2 75.5 ± 17.5
 End-exercise MRFD (N m s) 1330 ± 471 1230 ± 433
 End-exercise VA (%) 59 ± 19 62 ± 16
 End-exercise M-wave amplitude (%) 96 ± 14 95 ± 18
 End-exercise M-wave amplitude (mV) 5.64 ± 2.59 5.44 ± 2.72
 End-exercise EMG amplitude (%) 59 ± 17 87 ± 28*
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Using six contraction (30-s) bin means,  EMGRMS 
decreased from 99 ± 4% to 59 ± 17% in the PL trial (from 
first six to last six contractions; P < 0.0001, η2 = 0.502; 
Fig. 5). This decline in  EMGRMS was attenuated following 
ACT ingestion (100 ± 5 to 87 ± 28%), demonstrating a sig-
nificant main effect of condition (P = 0.033, η2 = 0.381) and 
an interaction effect (P = 0.043, η2 = 0.229). The  EMGRMS 
was elevated at 60 s (P = 0.036, d = 0.730), 90 s (P = 0.020, 
d = 0.835), 210 s (P = 0.040, d = 0.872), 240 s (P = 0.015, 
d = 0.886), 270 s (P = 0.019, d = 0.844) and 300 s (P = 0.001, 
d = 1.306) in ACT compared to PL (Fig. 5). As time pro-
gressed, the difference in EMG amplitude between condi-
tions increased as evidenced by a significant difference in 
rates of change between conditions (i.e., difference between 
300 and 150 s time points; P = 0.024, Cohen’s d = 0.804).
Discussion
Consistent with our experimental hypotheses, the princi-
pal findings of this study were that acute ACT ingestion 
increased mean MVC torque, and increased CT and EMG 
amplitude during the latter stages of the 60 MVC protocol. 
These observations offer insights into the mechanisms by 
which ACT blunts fatigue development and suggest that the 
ergogenic effect of ACT ingestion may be linked to increases 
in CT and muscle activation during fatiguing skeletal muscle 
contractions.
In the present study, fatigue development and some of 
its underpinning mechanisms were assessed during the 
completion of 60 MVCs of the knee extensors using the 
protocol described by Burnley (2009). Consistent with 
Burnley (2009), torque and pTw declined by 60% and 30%, 
respectively, and VA declined to 59%, reflecting peripheral 
and central fatigue development. However, although neuro-
muscular fatigue was also manifest during the ACT trial, the 
acute ingestion of ACT increased the mean torque during 
the fatiguing 60 MVC protocol by ~ 5% compared to the PL 
condition. This finding is in line with previous observations 
that acute ACT ingestion can improve performance during 
whole body exercise in humans (Foster et al. 2014; Mauger 
et al. 2010).
The attenuation of neuromuscular fatigue development 
following ACT ingestion was not accompanied by spe-
cific alterations in central fatigue (voluntary activation), 
peripheral fatigue (potentiated twitch, pTw) or peripheral 
neuromuscular excitability (M-wave) between the ACT 
Fig. 3  Group mean total impulse values in the placebo (PL) and 
acetaminophen (ACT) conditions are shown in the open and closed 
bars, respectively. Individual responses in the PLA and ACT con-
ditions are shown by the open circles and linked with dashed lines. 
*Significantly different from PLA (P < 0.05)
Fig. 4  Mean ± SE potentiated twitch (a), voluntary activation (b), and 
M-wave amplitude (c) responses during the 60 maximal voluntary 
contraction (MVC) test for placebo (clear circles) and acetaminophen 
(filled circles) trials
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and placebo trials. However, while EMG declined across 
the 60 MVC protocol in both conditions, it declined to a 
lesser extent with ACT (declined to ~ 87%) compared to PL 
(declined to ~ 59%). This observation suggests that improved 
muscle activation might have contributed to the ergogenic 
effect of ACT ingestion. This interpretation is strengthened 
by our observation of a positive correlation between the 
inter-trial changes in EMG and torque (r = 0.85). Although 
ACT ingestion has previously been reported to increase cor-
tico-spinal excitability at rest (Mauger and Hopker 2013), 
the neuromuscular mechanisms for improved performance 
during exercise had not been explored in previous studies 
reporting an ergogenic effect of ACT ingestion (Foster et al. 
2014; Mauger et al. 2010, 2014). Therefore, by suggesting 
that ACT can improve muscle activation during repeated 
fatiguing skeletal muscle contractions, our findings extend 
previous observations by providing insight into the poten-
tial neuromuscular bases for the ergogenic effect of ACT 
ingestion.
It is possible that the effect of ACT may be linked to a 
sub-conscious neuromuscular alteration during exercise 
via a reduction in the magnitude of muscle afferent feed-
back. During exercise, ascending group III and IV muscle 
afferents discharge in response to noxious, metabolic and 
mechanical stimuli within the contracting skeletal mus-
cles to regulate the sensation of pain, muscle activation 
and peripheral fatigue development (Amann et al. 2009, 
2011; Blain et al. 2016; Hureau et al. 2016; McCord and 
Kaufmann 2010; Pollak et al. 2014). When the magnitude 
of type III and IV muscle afferent feedback is reduced, per-
formance is compromised and pacing strategy is adversely 
impacted (Amann et al. 2009, 2011; Blain et al. 2016), 
despite enhanced muscle activation, as peripheral fatigue 
development is exacerbated. ACT administration, on the 
other hand, which seemingly acts predominantly through 
central processes to blunt pain sensation (Anderson 2008; 
Graham et al. 2013; Smith 2009; Toussaint et al. 2010), 
appears to have attenuated the decline in muscle activa-
tion without impacting peripheral fatigue development, 
Fig. 5  Surface electro-
myography (EMG) responses 
(expressed relative to M-wave 
amplitude) during the 60 MVC 
test for placebo (clear circles) 
and acetaminophen (filled 
circles) trials. Mean ± SE EMG 
responses are presented in a 
with the EMG response from a 
representative individual pre-
sented in b, for the 5th and 55th 
contractions, respectively, for 
PL (grey line) and ACT (black 
line). Individual representative 
data for M-wave can be seen 
in panel C for the 6th and 54th 
contractions, respectively, for 
PL (grey line) and ACT (black 
line). *Significantly different 
from placebo (P < 0.05)
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culminating in blunted neuromuscular fatigue development 
in the current study. Taken together, these observations 
suggest that reducing, but not abolishing, pain sensation 
can attenuate neuromuscular fatigue development during 
exercise or that a higher magnitude of afferent feedback is 
needed to trigger a given pain sensation. Nonetheless our 
findings, whilst suggesting that improved maintenance of 
muscle activation might have contributed to the ergogenic 
effect of ACT ingestion, cannot differentiate between a 
sub-conscious alteration in neuromuscular control or a 
conscious ability to increase muscle recruitment via a 
reduction in pain sensation.
The increased muscle activation in the latter stages of the 
ACT trial compared to the placebo trial was accompanied by 
a higher mean torque over the final 12 MVCs, and therefore 
a higher CT (Burnley 2009). The CT is an important physi-
ological threshold that is linked to neuromuscular fatigue 
development through influencing muscle metabolic homeo-
stasis (Jones et al. 2008; Vanhatalo et al. 2016), systemic 
respiratory and acid-base profiles (Poole et al. 1988) and 
neuromuscular function (Burnley et al. 2012). During the 
60 MVC protocol employed in the current study, there is a 
precipitous perturbation to skeletal muscle homeostasis, cen-
tral and peripheral fatigue development, a decline in muscle 
activation and a hyperbolic reduction in torque that asymp-
totes at CT (Burnley 2009; Burnley et al. 2010). By lower-
ing pain sensation (Foster et al. 2014; Mauger et al. 2010), 
ACT might have permitted the attainment of a greater degree 
of intramuscular metabolic perturbation, thereby leading to 
improved exercise tolerance. However, since potentiated 
twitch was not different between the ACT and placebo tri-
als, it appears that ACT ingestion did not result in greater 
peripheral fatigue development in this study. Instead, ACT 
ingestion enhanced muscle activation and increased CT over 
the latter stages of the 60 MVC protocol. Therefore, it is also 
possible that ACT ingestion lowered fatigue development 
through permitting greater muscle activation for a given 
degree of intramuscular metabolic perturbation.
The blunted neuromuscular fatigue development in this 
study occurred in association with increased muscle activa-
tion. However, it is surprising that the attenuation in neu-
romuscular fatigue development was not accompanied by 
changes in central (i.e., voluntary activation) or peripheral 
(i.e., potentiated twitch force) fatigue. Indeed, since muscle 
activation and torque were increased, this might be expected 
to result in greater intramuscular metabolic perturbation 
and, by extension, greater peripheral fatigue development. 
Although we cannot exclude the possibility that ACT 
enhanced systemic physiological responses or skeletal mus-
cle efficiency to mitigate this potential for greater peripheral 
fatigue development, we are not aware of any published evi-
dence to support such effects.
Experimental considerations
It is acknowledged that a limitation of the current study 
was that pain sensations were not directly assessed. Pain 
was not assessed due to the protocol requiring the comple-
tion of 60 MVCs with a short (2 s) recovery period; ask-
ing the subjects to rate pain sensation in this setting may 
have compromised their ability to focus on the exercise 
task and provide a true maximal effort during the experi-
mental protocol. Previous studies have observed a higher 
power output for the same pain sensation, suggestive of a 
reduction in the sensation of pain during cycle ergometry 
exercise (Foster et al. 2014; Mauger et al. 2010). How-
ever, these studies used a higher ACT dose (1.5 g) and a 
different exercise modality (cycling) compared to the cur-
rent study. Therefore, we are unable to draw conclusions 
regarding pain sensation with ACT in the current study. It 
should also be acknowledged that in the face of a relatively 
small (~ 5%) improvement in torque, it is possible that the 
central and peripheral fatigue measurements in our study 
were not sensitive enough to detect small defects in central 
nervous system and peripheral muscle function. Moreover, 
while ACT increased EMG during the latter stages of the 
60 MVC protocol compared to placebo, which might be 
linked, in part, to increased muscle activation and central 
motor drive, VA was not impacted by ACT. This might 
have been a function of the continuous assessment of the 
EMG response and torque throughout the 60 MVC proto-
col, compared to every 6th MVC for VA, such that EMG 
might have provided a more complete picture of central 
fatigue development across the protocol. Recent research 
has also challenged the validity of VA estimated using 
the interpolated twitch technique as a measure of central 
fatigue (Neyroud et al. 2016), which might contribute to 
the disparity between the EMG-inferred central motor 
drive and the VA results. Accordingly, further research 
is required to resolve the underlying mechanisms for the 
ergogenic effect of ACT ingestion.
Although the current study is consistent with previous 
studies reporting an ergogenic effect of acute ACT con-
sumption (Foster et al. 2014; Mauger et al. 2010, 2014), 
we do not advocate regular ACT use or exceeding a sin-
gle dose of 1 g given the potent hepatotoxicity of ACT 
ingestion (Graham et al. 2013). Therefore, individuals 
wishing to explore the use of ACT to enhance exercise 
performance should do so infrequently, and with caution.
In conclusion, acute ACT ingestion increased the mean 
torque across 60 MVCs of the knee extensors in agreement 
with earlier reports that ACT can attenuate neuromuscular 
fatigue development and improve exercise performance. 
Our results extend these previous observations by providing 
novel insights into the mechanisms for the potential ergo-
genic effect of ACT ingestion. Specifically, the improved 
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mean torque was accompanied by an increase in CT and 
greater muscle activation during the latter stages of the 60 
MVC protocol. Therefore, ACT ingestion appears to atten-
uate fatigue development during repeated skeletal muscle 
MVCs by enabling a better preservation of muscle activation 
during exercise.
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